Global Tumor Necrosis Factor Inhibitors Drug Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Tumor Necrosis Factor Inhibitors Drug Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Product
  • 1.4.2 Cimzia (Certolizumab Pegol)
  • 1.4.3 Enbrel (Etanercept)
  • 1.4.4 Humira ( Adalimumab)
  • 1.4.5 Otezla (Apremilast)
  • 1.4.6 Remicade (Infliximab)
  • 1.4.7 Simponi (Golimumab)
• 1.5 Market by End User
  • 1.5.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by End User
  • 1.5.2 Clinic
  • 1.5.3 Hospital
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size
  • 2.1.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue 2014-2025
  • 2.1.2 Global Tumor Necrosis Factor Inhibitors Drug Sales 2014-2025
• 2.2 Tumor Necrosis Factor Inhibitors Drug Growth Rate by Regions
  • 2.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Regions
  • 2.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturers
  • 3.1.1 Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturers
  • 3.1.2 Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Manufacturers
  • 3.1.3 Global Tumor Necrosis Factor Inhibitors Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers
  • 3.2.1 Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers (2014-2019)
  • 3.2.2 Tumor Necrosis Factor Inhibitors Drug Revenue Share by Manufacturers (2014-2019)
• 3.3 Tumor Necrosis Factor Inhibitors Drug Price by Manufacturers
• 3.4 Tumor Necrosis Factor Inhibitors Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Tumor Necrosis Factor Inhibitors Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Tumor Necrosis Factor Inhibitors Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Tumor Necrosis Factor Inhibitors Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Product
• 4.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Product
• 4.3 Tumor Necrosis Factor Inhibitors Drug Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Tumor Necrosis Factor Inhibitors Drug Breakdown Data by End User

6 North America

• 6.1 North America Tumor Necrosis Factor Inhibitors Drug by Countries
  • 6.1.1 North America Tumor Necrosis Factor Inhibitors Drug Sales by Countries
  • 6.1.2 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Tumor Necrosis Factor Inhibitors Drug by Product
• 6.3 North America Tumor Necrosis Factor Inhibitors Drug by End User

7 Europe

• 7.1 Europe Tumor Necrosis Factor Inhibitors Drug by Countries
  • 7.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Countries
  • 7.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Tumor Necrosis Factor Inhibitors Drug by Product
• 7.3 Europe Tumor Necrosis Factor Inhibitors Drug by End User

8 Asia Pacific

• 8.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug by Countries
  • 8.1.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Countries
  • 8.1.2 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Tumor Necrosis Factor Inhibitors Drug by Product
• 8.3 Asia Pacific Tumor Necrosis Factor Inhibitors Drug by End User

9 Central & South America

• 9.1 Central & South America Tumor Necrosis Factor Inhibitors Drug by Countries
  • 9.1.1 Central & South America Tumor Necrosis Factor Inhibitors Drug Sales by Countries
  • 9.1.2 Central & South America Tumor Necrosis Factor Inhibitors Drug Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Tumor Necrosis Factor Inhibitors Drug by Product
• 9.3 Central & South America Tumor Necrosis Factor Inhibitors Drug by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug by Countries
  • 10.1.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Countries
  • 10.1.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug by Product
• 10.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug by End User

11 Company Profiles

• 11.1 Apogenix
  • 11.1.1 Apogenix Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Apogenix Tumor Necrosis Factor Inhibitors Drug Products Offered
  • 11.1.5 Apogenix Recent Development
• 11.2 AryoGen Biopharma
  • 11.2.1 AryoGen Biopharma Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Products Offered
  • 11.2.5 AryoGen Biopharma Recent Development
• 11.3 Bionovis
  • 11.3.1 Bionovis Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Bionovis Tumor Necrosis Factor Inhibitors Drug Products Offered
  • 11.3.5 Bionovis Recent Development
• 11.4 CASI Pharmaceuticals
  • 11.4.1 CASI Pharmaceuticals Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
  • 11.4.5 CASI Pharmaceuticals Recent Development
• 11.5 Celltrion
  • 11.5.1 Celltrion Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Celltrion Tumor Necrosis Factor Inhibitors Drug Products Offered
  • 11.5.5 Celltrion Recent Development
• 11.6 Celgene Corporation
  • 11.6.1 Celgene Corporation Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Products Offered
  • 11.6.5 Celgene Corporation Recent Development
• 11.7 Delenex Therapeutics
  • 11.7.1 Delenex Therapeutics Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Products Offered
  • 11.7.5 Delenex Therapeutics Recent Development
• 11.8 Dexa Medica
  • 11.8.1 Dexa Medica Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Products Offered
  • 11.8.5 Dexa Medica Recent Development
• 11.9 EPIRUS Biopharmaceuticals
  • 11.9.1 EPIRUS Biopharmaceuticals Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
  • 11.9.5 EPIRUS Biopharmaceuticals Recent Development
• 11.10 Janssen Biotech
  • 11.10.1 Janssen Biotech Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Products Offered
  • 11.10.5 Janssen Biotech Recent Development
• 11.11 GlaxoSmithKline
• 11.12 HanAll Biopharma
• 11.13 Intas Pharmaceuticals
• 11.14 LEO Pharma
• 11.15 LG Life Sciences
• 11.16 MedImmune
• 11.17 Momenta Pharmaceuticals
• 11.18 Novartis
• 11.19 PROBIOMED
• 11.20 Reliance Life Sciences
• 11.21 Sandoz
• 11.22 Samsung Bioepis
• 11.23 Sanofi-Aventis
• 11.24 Shanghai CP Guojian Pharmaceutical
• 11.25 Shanghai Pharmaceuticals
• 11.26 Simcere Pharmaceutical
• 11.27 Toyama Chemical
• 11.28 Tsumura
• 11.29 UCB
• 11.30 Zydus Cadila

12 Future Forecast

• 12.1 Tumor Necrosis Factor Inhibitors Drug Market Forecast by Regions
  • 12.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Regions 2019-2025
• 12.2 Tumor Necrosis Factor Inhibitors Drug Market Forecast by Product
  • 12.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Product 2019-2025
  • 12.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Product 2019-2025
• 12.3 Tumor Necrosis Factor Inhibitors Drug Market Forecast by End User
• 12.4 North America Tumor Necrosis Factor Inhibitors Drug Forecast
• 12.5 Europe Tumor Necrosis Factor Inhibitors Drug Forecast
• 12.6 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Forecast
• 12.7 Central & South America Tumor Necrosis Factor Inhibitors Drug Forecast
• 12.8 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Tumor Necrosis Factor Inhibitors Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details